| Project/Area Number |
16K19584
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Masaki Ayako 名古屋市立大学, 大学院医学研究科, 講師 (40648044)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | IDO / Malignant lymphoma / Tumor immunity / 悪性リンパ腫 / 抗腫瘍免疫 / 造血器悪性腫瘍 / 免疫療法 |
|---|
| Outline of Final Research Achievements |
Indoleamine 2,3-dioxygenase 1 (IDO) is one of enzyme catabolizing tryptophan into the kynurenine pathway, and recognized as an important microenvironmental factor suppressing antitumor immune responses. Quantification of serum Kyn and Trp is useful for predicting prognosis of an individual patients with hematological malignancy, such as adult T-cell leukemia/lymphoma, Hodgkin lymphoma, and follicular lymphoma. Furthermore, it is thought that IDO is an attractive novel cancer immunotherapies target in various hematological malignancy.
|
